Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects ≥1 Month to <4 Years With Partial-onset Seizures

PHASE3CompletedINTERVENTIONAL
Enrollment

255

Participants

Timeline

Start Date

June 5, 2015

Primary Completion Date

May 28, 2020

Study Completion Date

May 28, 2020

Conditions
Epilepsy With Partial-onset Seizures
Interventions
DRUG

Lacosamide

Active Substance: Lacosamide Pharmaceutical Form: Syrup Concentration: 10 mg/mL Route of Administration: oral

OTHER

Placebo

Active Substance: Placebo Pharmaceutical Form: Syrup Concentration: N/A Route of Administration: oral

Trial Locations (88)

33609

Sp0967 117, Tampa

35233

Sp0967 638, Birmingham

75235

Sp0967 129, Dallas

78207

Sp0967 630, San Antonio

78249

Sp0967 643, San Antonio

89052

Sp0967 115, Henderson

03756

Sp0967 120, Lebanon

Unknown

Sp0967 142, Córdoba

Sp0967 158, Passo Fundo

Sp0967 152, Porto Alegre

Sp0967 150, São Paulo

Sp0967 154, São Paulo

Sp0967 310, Plovdiv

Sp0967 530, Beijing

Sp0967 535, Changchun

Sp0967 532, Chongqing

Sp0967 536, Nanchang

Sp0967 531, Shanghai

Sp0967 537, Shenzhen

Sp0967 613, Osijek

Sp0967 610, Rijeka

Sp0967 612, Zagreb

Sp0967 320, Ostrava-Poruba

Sp0967 349, Marseille

Sp0967 346, Rennes

Sp0967 344, Strasbourg

Sp0967 620, Tbilisi

Sp0967 621, Tbilisi

Sp0967 622, Tbilisi

Sp0967 623, Tbilisi

Sp0967 542, Athens

Sp0967 361, Budapest

Sp0967 362, Budapest

Sp0967 363, Budapest

Sp0967 364, Budapest

Sp0967 368, Budapest

Sp0967 374, Petah Tikva

Sp0967 397, Genova

Sp0967 398, Messina

Sp0967 381, Milan

Sp0967 700, Napoli

Sp0967 383, Roma

Sp0967 395, Roma

Sp0967 694, Aguascalientes

Sp0967 561, Chihuahua City

Sp0967 569, Culiacán

Sp0967 693, Culiacán

Sp0967 563, Guadalajara

Sp0967 564, México

Sp0967 568, Monterrey

Sp0967 692, Monterrey

Sp0967 650, Chisinau

Sp0967 720, Cebu

Sp0967 724, Cebu

Sp0967 721, Manila

Sp0967 723, Manila

Sp0967 727, Quezon City

Sp0967 422, Krakow

Sp0967 750, Lisbon

Sp0967 581, Bucharest

Sp0967 582, Iași

Sp0967 573, Sibiu

Sp0967 577, Timișoara

Sp0967 454, Kemerovo

Sp0967 456, Nizhny Novgorod

Sp0967 452, Novosibirsk

Sp0967 453, Omsk

Sp0967 455, Perm

Sp0967 730, Smolensk

Sp0967 458, Tomsk

Sp0967 459, Ulyanovsk

Sp0967 450, Yekaterinburg

Sp0967 461, Belgrade

Sp0967 464, Belgrade

Sp0967 463, Novi Sad

Sp0967 474, Bratislava

Sp0967 212, Seoul

Sp0967 215, Seoul

Sp0967 224, Taipei

Sp0967 237, Bangkok

Sp0967 235, Pathum Wan

Sp0967 602, Dnipro

Sp0967 609, Dnipro

Sp0967 681, Ivano-Frankivsk

Sp0967 600, Kiev

Sp0967 606, Kiev

Sp0967 682, Uzhhorod

Sp0967 603, Vinnytsia

All Listed Sponsors
lead

UCB BIOSCIENCES, Inc.

INDUSTRY

NCT02477839 - Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects ≥1 Month to <4 Years With Partial-onset Seizures | Biotech Hunter | Biotech Hunter